Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Cell fate conversion prediction by group sparse optimization method utilizing single-cell and bulk OMICs data
Qin, Jing , Yao, Jen‐Chih , Leung, Ricky Wai Tak , Zhou, Yongqiang, Qin, Yiming , Wang, Junwen , Wang, Junwen , Qin, Jing , Hu, Yaohua

Mayo Clinic

Briefings in Bioinformatics | July 21, 2021 | Volume: 22 | Issue: 6 | Pages: No page available

10.1093/bib/bbab311 | PMID 34374760 Get It

Abstract Cell fate conversion by overexpressing defined factors is a powerful tool in regenerative medicine. However, identifying key factors for cell fate conversion requires laborious experimental efforts; thus, many of such conversions have not been achieved yet. Nevertheless, cell fate conversions found in many published studies were incomplete as the expression of important gene sets could not be manipulated thoroughly. Therefore, the identification of master transcription factors for complete and efficient conversion is crucial to render this technology more applicable clinically. In the past decade, systematic analyses on various single-cell and bulk OMICs data have uncovered numerous gene regulatory mechanisms, and made it possible to predict master gene regulators during cell fate conversion. By virtue of the sparse structure of master transcription factors and the group structure of their simultaneous regulatory effects on the cell fate conversion process, this study introduces a novel computational method predicting master transcription factors based on group sparse optimization technique integrating data from multi-OMICs levels, which can be applicable to both single-cell and bulk OMICs data with a high tolerance of data sparsity. When it is compared with current prediction methods by cross-referencing published and validated master transcription factors, it possesses superior performance. In short, this method facilitates fast identification of key regulators, give raise to the possibility of higher successful conversion rate and in the hope of reducing experimental cost.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Miguel, Jesús F. San , Usmani, Saad Z. , Paiva, Bruno , Plesner, Torben , Hungria, Vânia , Moreau, Philippe , Mateos, María‐Victoria , Perrot, Aurore , Iida, Shinsuke , Kumar, Shaji , Donk, Niels W.C.J. van de , Sonneveld, Pieter , Spencer, Andrew , Krevvata, Maria, Heuck, Christoph, Wang, Jianping , Ukropec, Jon, Kobos, Rachel, Sun, Steven , Qi, Mia, Munshi, Nikhil C. , San-Miguel, Jesus , Paiva, Bruno , Hungria, Vania , Mateos, María-Victoria , Perrot, Aurore , Iida, Shinsuke , Kumar, Shaji K , Moreau, Philippe , Usmani, Saad , Cavo, Michèle , Weisel, Katja C , Dimopoulos, Meletios Α. , Avet‐Loiseau, Hervé , Bahlis, Nizar Jacques , Facon, Thierry T.F.

Mayo Clinic

Blood | July 21, 2021 | Volume: 139 | Issue: 6 | Pages: 835-844

10.1182/blood.2021011101 | PMID 34289038 Get It

Abstract We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previously demonstrated that daratumumab-based therapies improved MRD negativity rates and reduced the risk of disease progression or death by approximately half vs standards of care. We conducted a large-scale pooled analysis for associations between patients achieving complete response or better (≥CR) with MRD-negative status and progression-free survival (PFS). MRD was assessed via next-generation sequencing (10−5 sensitivity threshold). Patient-level data were pooled from all 4 studies and for patients with TIE NDMM and patients with RRMM who received ≤2 prior lines of therapy (≤2 PL). PFS was evaluated by response and MRD status. Median follow-up (months) was 54.8 for POLLUX, 50.2 for CASTOR, 40.1 for ALCYONE, and 36.4 for MAIA. Patients who achieved ≥CR and MRD negativity had improved PFS vs those who failed to reach CR or were MRD positive (TIE NDMM and RRMM hazard ratio [HR] 0.20, P < .0001; TIE NDMM and RRMM ≤2 PL HR 0.20, P < .0001). This benefit occurred irrespective of therapy or disease setting. A time-varying Cox proportional hazard model confirmed that ≥CR with MRD negativity was associated with improved PFS. Daratumumab-based treatment was associated with more patients reaching ≥CR and MRD negativity. These findings represent the first large-scale analysis with robust methodology to support ≥CR with MRD negativity as a prognostic factor for PFS in RRMM and TIE NDMM. These trials were registered at www.clinicaltrials.gov as #NCT02076009, #NCT02136134, #NCT02195479, and #NCT02252172.
Pan‐cancer analysis of prognostic metastatic phenotypes
Wang, Xi , Garrett, Sara M. , Lehrer, Eric J. , Lin, Christine , DeGraff, David J. , Spratt, Daniel E. , Kishan, Amar U. , Park, Henry S. , Yang, Jonathan T. , Zaorsky, Nicholas G , Garrett, Sara M , Spratt, Daniel E , Park, Henry S , Zaorsky, Nicholas G. , Trifiletti, Daniel M. , Showalter, Timothy N. , Chinchilli, Vernon M , Wang, Ming

Mayo Clinic

International Journal of Cancer | July 20, 2021 | Volume: 150 | Issue: 1 | Pages: 132-141

10.1002/ijc.33744 | PMID 34287840 Get It

AbstractAlthough cancer is highly heterogeneous, all metastatic cancer is considered American Joint Committee on Cancer (AJCC) Stage IV disease. The purpose of this project was to redefine staging of metastatic cancer. Internal validation of nationally representative patient data from the National Cancer Database (n = 461 357; 2010‐2013), and external validation using the Surveillance, Epidemiology and End Results database (n = 106 595; 2014‐2015) were assessed using the concordance index for evaluation of survival prediction. A Cox proportional hazards model was used for overall survival by considering identified phenotypes (latent classes) and other confounding variables. Latent class analysis was performed for phenotype identification, where Bayesian information criterion (BIC) and sample‐size‐adjusted BIC were used to select the optimal number of distinct clusters. Kappa coefficients assessed external cluster validation. Latent class analysis identified five metastatic phenotypes with differences in overall survival (P < .0001): (Stage IVA) nearly exclusive bone‐only metastases (n = 59 049, 12.8%; median survival 12.7 months; common in lung, breast and prostate cancers); (IVB) predominant lung metastases (n = 62 491, 13.5%; 11.4 months; common in breast, stomach, kidney, ovary, uterus, thyroid, cervix and soft tissue cancers); (IVC) predominant liver/lung metastases (n = 130 014, 28.2%; 7.0 months; common in colorectum, pancreatic, lung, esophagus and stomach cancers); (IVD) bone/liver/lung metastases predominant over brain (n = 61 004, 13.2%; 5.9 months; common in lung and breast cancers); and (IVE) brain/lung metastases predominant over bone/liver (n = 148 799, 32.3%; 5.7 months; lung cancer and melanoma). Long‐term survivors were identified, particularly in Stages IVA‐B. A pan‐cancer nomogram model to predict survival (STARS: site, tumor, age, race, sex) was created, validated and provides 13% better prognostication than AJCC: 1‐month concordance index of 0.67 (95% confidence interval [CI]: 0.66‐0.67) vs 0.61 (95% CI: 0.60‐0.61). STARS is simple, uses easily accessible variables, better prognosticates survival outcomes and provides a platform to develop novel metastasis‐directed clinical trials.
Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer
Daydé, Delphine , Hirayama, Yutaka, Weksberg, David C., Boutin, Adam T., Parhy, Gargy, Aguilar-Bonavides, Clemente , Katayama, Hiroyuki , Abe, Yuichi , Kinoshita, Takashi , Komori, Koji , Shimizu, Yasuhiro , Niwa, Yasumasa, Wang, Yanru , DePinho, Ronald A. , Krishnan, Sunil, Taguchi, Ayumu , Katayama, Hiroyuki , Taguchi, Ayumu , DePinho, Ronald A , Gunther, Jillian Rebecca , Wang, Hong , Do, Kim‐Anh , Hara, Kazuo , Tajika, Masahiro , Hanash, Samir

Mayo Clinic

Cancers | July 20, 2021 | Volume: 13 | Issue: 14 | Pages: 3642

10.3390/cancers13143642 | PMID 34298853 Get It

The current standard of care for patients with locally advanced rectal cancer (LARC) is neoadjuvant chemoradiation (nCRT) followed by total mesorectal excision surgery. However, the response to nCRT varies among patients and only about 20% of LARC patients achieve a pathologic complete response (pCR) at the time of surgery. Therefore, there is an unmet need for biomarkers that could predict the response to nCRT at an early time point, allowing for the selection of LARC patients who would or would not benefit from nCRT. To identify blood-based biomarkers for prediction of nCRT response, we performed in-depth quantitative proteomic analysis of pretreatment plasma from mice bearing rectal tumors treated with concurrent chemoradiation, resulting in the quantification of 567 proteins. Among the plasma proteins that increased in mice with residual rectal tumor after chemoradiation compared to mice that achieved regression, we selected three proteins (Vascular endothelial growth factor receptor 3 [VEGFR3], Insulin like growth factor binding protein 4 [IGFBP4], and Cathepsin B [CTSB]) for validation in human plasma samples. In addition, we explored whether four tissue protein biomarkers previously shown to predict response to nCRT (Epidermal growth factor receptor [EGFR], Ki-67, E-cadherin, and Prostaglandin G/H synthase 2 [COX2]) also act as potential blood biomarkers. Using immunoassays for these seven biomarker candidates as well as Carcinoembryonic antigen [CEA] levels on plasma collected before nCRT from 34 patients with LARC (6 pCR and 28 non-pCR), we observed that levels of VEGFR3 (p = 0.0451, AUC = 0.720), EGFR (p = 0.0128, AUC = 0.679), and COX2 (p = 0.0397, AUC = 0.679) were significantly increased in the plasma of non-pCR LARC patients compared to those of pCR LARC patients. The performance of the logistic regression model combining VEGFR3, EGFR, and COX2 was significantly improved compared with the performance of each biomarker, yielding an AUC of 0.869 (sensitivity 43% at 95% specificity). Levels of VEGFR3 and EGFR were significantly decreased 5 to 7 months after tumor resection in plasma from 18 surgically resected rectal cancer patients, suggesting that VEGFR3 and EGFR may emanate from tumors. These findings suggest that circulating VEGFR3 can contribute to the prediction of the nCRT response in LARC patients together with circulating EGFR and COX2.
Association between anemia and ICU outcomes
Song, Xuan , Liu, Xinyan , Wang, Huai-Rong, Guo, Xiuyan, Ma, Penglin , Kashani, Kianoush

Mayo Clinic

Chinese Medical Journal | July 20, 2021 | Volume: 134 | Issue: 14 | Pages: 1744-1746

10.1097/cm9.0000000000001669 | PMID 34397599 Get It

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Guidon, Amanda C. , Burton, Leeann B , Chwalisz, Bart K. , Hillis, James , Schaller, Teilo , Amato, Anthony A., Warner, Allison Betof , Cho, Tracey , Clardy, Stacey , Dietrich, Jörg , Dougan, Michael , Doughty, Christopher , Dubey, Divyanshu , Guptill, Jeffrey T. , Johnson, Douglas B. , Juel, Vern C. , Kadish, Robert , Kolb, Noah , LeBoeuf, Nicole R. , Linnoila, Jenny, Mammen, Andrew L. , Martinez‐Lage, Maria , Mooradian, Meghan J. , Naidoo, Jarushka , Neilan, Tomas G. , Reardon, David A. , Rubin, Krista M., Santomasso, Bianca , Sullivan, Ryan J. , Woodman, Karin , Zubiri, Leyre , Louv, William C, Reynolds, Kerry L. , Amato, Anthony A. , Betof Warner, Allison , Dougan, Michael , Mooradian, Meghan J , Naidoo, Jarushka , Sullivan, Ryan J , Zubiri, Leyre , Kolb, Noah A , Clardy, Stacey L , Dubey, Divyanshu , Martinez-Lage, Maria , Cho, Tracey A , Brastianos, Priscilla K. , Cohen, Justine Vanessa , Gelfand, Jeffrey M. , Wang, Nancy

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 19, 2021 | Volume: 9 | Issue: 7 | Pages: e002890

10.1136/jitc-2021-002890 | PMID 34281989 Get It

Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%–12% and a high fatality rate relative to other irAEs. Lack of standardized disease definitions and accurate phenotyping leads to syndrome misclassification and impedes development of evidence-based treatments and translational research. The objective of this study was to develop consensus guidance for an approach to irAE-Ns including disease definitions and severity grading. A working group of four neurologists drafted irAE-N consensus guidance and definitions, which were reviewed by the multidisciplinary Neuro irAE Disease Definition Panel including oncologists and irAE experts. A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND/University of California Los Angeles (UCLA) Appropriateness Method with prespecified definitions. 27 panelists from 15 academic medical centers voted on a total of 53 rating scales (6 general guidance, 24 central and 18 peripheral nervous system disease definition components, 3 severity criteria and 2 clinical trial adjudication statements); of these, 77% (41/53) received first round consensus. After revisions, all items received second round consensus. Consensus definitions were achieved for seven core disorders: irMeningitis, irEncephalitis, irDemyelinating disease, irVasculitis, irNeuropathy, irNeuromuscular junction disorders and irMyopathy. For each disorder, six descriptors of diagnostic components are used: disease subtype, diagnostic certainty, severity, autoantibody association, exacerbation of pre-existing disease or de novo presentation, and presence or absence of concurrent irAE(s). These disease definitions standardize irAE-N classification. Diagnostic certainty is not always directly linked to certainty to treat as an irAE-N (ie, one might treat events in the probable or possible category). Given consensus on accuracy and usability from a representative panel group, we anticipate that the definitions will be used broadly across clinical and research settings.
Occupational insecticide exposure and risk of non‐Hodgkin lymphoma: A pooled case‐control study from the InterLymph Consortium
Roos, Anneclaire J. De , Schinasi, Leah H. , Miligi, Lucia , Cerhan, James R. , Bhatti, Parveen , Baris, Dalsu , Benavente, Yolanda , Benke, Geza , Clavel, Jacqueline , Casabonne, Delphine, Monnereau, Alain , Vajdic, Claire M. , Wang, Sophia , Zhang, Yawei, Cocco, Pierluigi , De Roos, Anneclaire J , Vajdic, Claire M , Cerhan, James R , Cocco, Pierluigi , Wang, Sophia S , Bhatti, Parveen , Clavel, Jacqueline , Mannetje, Andrea ’t , Casabonne, Delphine , Fritschi, Lin , Hofmann, Jonathan N. , Huynh, Tran , Piro, Sara , Slager, Susan L. , Zhang, Yawei, Bernstein, Leslie

Mayo Clinic

International Journal of Cancer | July 16, 2021 | Volume: 149 | Issue: 10 | Pages: 1768-1786

10.1002/ijc.33740 | PMID 34270795 Get It

AbstractEvidence for the human health effects of pesticides is needed to inform risk assessment. We studied the relationship between occupational insecticide use and risk of non‐Hodgkin lymphoma (NHL) by pooling data from nine case‐control studies participating in the InterLymph Consortium, including 7909 cases and 8644 controls from North America, the European Union and Australia. Insecticide use was coded using self‐report or expert assessment, for insecticide groups (eg, organophosphates, pyrethroids) and active ingredients (eg, malathion, permethrin). Associations with insecticides were estimated using logistic regression to produce odds ratios (ORs) and 95% confidence intervals (CI) for all NHL and NHL subtypes, with adjustment for study site, demographic factors and use of other pesticides. Occupational insecticide use, overall, was not associated with risk of NHL. Use of organophosphate insecticides was associated with increased risk of all NHL and the subtype follicular lymphoma, and an association was found with diazinon, in particular (ever use: OR = 2.05, 95%CI: 1.24‐3.37). The carbamate insecticide, carbaryl, was associated with risk of all NHL, and the strongest associations were found with T‐cell NHL for ever‐use (OR = 2.44, 95%CI: 1.13‐5.28) and longer duration (>8 years vs never: OR = 2.90, 95%CI: 1.02‐8.25). There was no association of NHL with other broad groups of insecticides, including organochlorines and pyrethroids, and some inverse associations were estimated in relation to historical DDT use. Our findings contribute to the totality of evidence available to help inform risk decisions by public health and regulatory agencies of importance given continued, widespread use of organophosphate and carbamate insecticides.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Miguel, Jesús F. San , Paiva, Bruno , Kumar, Shaji , Mateos, María‐Victoria , Usmani, Saad Z. , Cook, Gordon , Cavo, Michèle , Quach, Hang , Ukropec, Jon, Ramaswami, Priya, Pei, Huiling , Qi, Mia, Sun, Steven , Wang, Jianping , Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Rampelbergh, Rian Van , Kudva, Anupa, Kobos, Rachel, Qi, Ming , San-Miguel, Jesus , Paiva, Bruno , Kumar, Shaji K , Mateos, María-Victoria , Quach, Hang , Cook, Gordon , Usmani, Saad , Avet‐Loiseau, Hervé , Dimopoulos, Meletios Α. , Facon, Thierry T.F. , Touzeau, Cyrille , Jakubowiak, Andrzej , Bahlis, Nizar Jacques

Mayo Clinic

Blood | July 16, 2021 | Volume: 139 | Issue: 4 | Pages: 492-501

10.1182/blood.2020010439 | PMID 34269818 Get It

Abstract In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10−5) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE).
Collaborative Writing Projects: Set Yourself up for Success
Catanzano, Tara, Robbins, Jessica B. , Schwartz, Fides R. , Rajiah, Prabhakar , Wang, Sherry S. , Soloff, Erik V. , Folio, Les , Rajiah, Prabhakar , Nandwana, Sadhna B.

Mayo Clinic

Journal of Computer Assisted Tomography | July 16, 2021 | Volume: 45 | Issue: 4 | Pages: 495-499

10.1097/rct.0000000000001187 | PMID 34270477 Get It

Abstract This article will review critical components for the successful completion of a multi-institution, multiauthor collaborative paper. Best practices for the creation and publication of a collaborative paper will be addressed.
Incorporation of quantitative MRI in a model to predict temporal lobe epilepsy surgery outcome
Morita‐Sherman, Marcia , Li, Manshi , Joseph, Boney , Yasuda, Clarissa Lin , Vegh, Deborah , Campos, Brunno Machado de , Alvim, Marina K. M. , Louis, Shreya , Bingaman, William , Najm, Imad , Jones, Stephen E. , Wang, Xiaofeng , Brinkmann, Benjamin H. , Blümcke, Ingmar , Brinkmann, Benjamin H , Yasuda, Clarissa L , Joseph, Boney , Najm, Imad , Morita, Márcia Elisabete , Blümcke, Ingmar , Worrell, Gregory A. , Cendes, Fernando , Jehi, Lara

Mayo Clinic

Brain Communications | July 15, 2021 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcab164 | PMID 34396113 Get It

Abstract Quantitative volumetric brain MRI measurement is important in research applications, but translating it into patient care is challenging. We explore the incorporation of clinical automated quantitative MRI measurements in statistical models predicting outcomes of surgery for temporal lobe epilepsy. Four hundred and thirty-five patients with drug-resistant epilepsy who underwent temporal lobe surgery at Cleveland Clinic, Mayo Clinic and University of Campinas were studied. We obtained volumetric measurements from the pre-operative T1-weighted MRI using NeuroQuant, a Food and Drug Administration approved software package. We created sets of statistical models to predict the probability of complete seizure-freedom or an Engel score of I at the last follow-up. The cohort was randomly split into training and testing sets, with a ratio of 7:3. Model discrimination was assessed using the concordance statistic (C-statistic). We compared four sets of models and selected the one with the highest concordance index. Volumetric differences in pre-surgical MRI located predominantly in the frontocentral and temporal regions were associated with poorer outcomes. The addition of volumetric measurements to the model with clinical variables alone increased the model’s C-statistic from 0.58 to 0.70 (right-sided surgery) and from 0.61 to 0.66 (left-sided surgery) for complete seizure freedom and from 0.62 to 0.67 (right-sided surgery) and from 0.68 to 0.73 (left-sided surgery) for an Engel I outcome score. 57% of patients with extra-temporal abnormalities were seizure-free at last follow-up, compared to 68% of those with no such abnormalities (P-value = 0.02). Adding quantitative MRI data increases the performance of a model developed to predict post-operative seizure outcomes. The distribution of the regions of interest included in the final model supports the notion that focal epilepsies are network disorders and that subtle cortical volume loss outside the surgical site influences seizure outcome.